NCT05080842View on ClinicalTrials.gov

A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

April 4, 2024

Study Completion Date

April 4, 2024

Conditions
Breast Cancer
Interventions
DRUG

AC682

Participants will receive AC682 by mouth daily in 28-day cycles.

Trial Locations (5)

32827

Site 04, Orlando

34232

Site 02, Sarasota

37203

Site 03, Nashville

77030

Site 05, Houston

80218

Site 01, Denver

Sponsors
All Listed Sponsors
lead

Accutar Biotechnology Inc

INDUSTRY

NCT05080842 - A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer | Biotech Hunter | Biotech Hunter